Thursday 16 October, 2025
Objectives: Non-linear mixed effects (NLME) modelling aims to estimate the population-level parameters and the distribution of individual-level parameters (random effects,…
Read moreAbstracts
nonmem2mrgsolve: An R package for Automated NONMEM to mrgsolve Translation
Thursday 16 October, 2025
Introduction: Pharmacometricians often utilize multiple software, with NONMEM® (ICON plc, Dublin, Ireland) widely regarded as the current gold standard for…
Read moreData-Driven Discovery of Interpretable Feedback Mechanisms in Acute Myeloid Leukaemia using DeepPumas
Thursday 16 October, 2025
In pharmacometrics, model derivation and selection are critical for quantitatively analyzing drug-biological interactions, elucidating pharmacokinetic/-dynamic (PKPD) relationships, and optimizing dosing…
Read moreAddressing Confounding Bias in Exposure-Response Analysis: Evaluating Instrumental Variable Modeling Strategies
Thursday 16 October, 2025
Objectives: Randomization of subjects to multiple dose levels in clinical trials enables an unbiased estimation of the dose-response relationship. However,…
Read moreExploring the contribution of brain metabolism in mechanistic understanding of Kp,uu,BBB – A case study for remoxipride
Thursday 16 October, 2025
Objectives: Kp,uu,BBB values are crucial indicators of drug distribution into the brain, representing the steady-state relationship between unbound concentrations in…
Read moreA multi-scale modelling framework to assess the relationship between SARS-CoV-2 viral load and transmission in household studies.
Thursday 16 October, 2025
Objectives: Our understanding of the dynamics of SARS-CoV-2 infection within a host and how it relates to an individual’s ability…
Read morePopulation pharmacokinetic modelling of oral ruxolitinib: a real-world prospective observational study
Thursday 16 October, 2025
Objectives: Ruxolitinib is a small molecule targeting JAK1 and JAK2 proteins and used orally for the treatment of myeloproliferative disorders, such…
Read moreIntegration of clinical data and mechanistic model simulations highlights key parameters for design and selection of successful ADCs
Thursday 16 October, 2025
Introduction/Objectives: Antibody-Drug Conjugates (ADCs) aim at exploiting the targeted nature of monoclonal antibodies (mAb) to selectively deliver cytotoxic payloads into…
Read moreModel-based meta-analysis of individual patient data from three independent datasets for the characterization of intravenous 5-fluorouracil population pharmacokinetics
Thursday 16 October, 2025
Introduction: For certain old, widely used therapies, a plethora of non-compartmental analyses and population pharmacokinetic (popPK) studies are available in…
Read moreIntroducing InSilicoTrials NONMEM simulator: Cloud-based simulation tool for NONMEM models
Thursday 16 October, 2025
Objectives: We are working to develop cloud based trial simulation tools that reduce the effort required to leverage existing pharmacometrics…
Read more